CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. PRIM
6. META
7. SPY
8. DPZ
9. NAVN
10. NVDA

Go back to CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

uniQure BV (QURE) Risk/Reward 'Heavily Skewed To The Upside' - Raymond James

May 6, 2021 9:44 AM EDT

Raymond James analyst Danielle Brill reiterated a Strong Buy rating and $75.00 price target on uniQure BV (NASDAQ: QURE) after announcing the licensing agreement with CSL Behring for its HemB gene therapy (etranacogene dezaparvovec (EtranaDez)) has closed.

"In our view, the hemophilia-B gene... More